Results 161 to 170 of about 433,450 (245)

Biomaterials for modulating cellular responses of endogenous tendon stem/progenitor cells: A promising avenue for tendon regeneration

open access: yesBMEMat, EarlyView.
This review comprehensively summarizes emerging biomaterial‐based strategies and underlying mechanisms for modulating endogenous tendon stem/progenitor cells (TSPCs). It offers the most recent insights into TSPC physiology and potential applications of tissue engineering and regenerative medicine in tendons.
Zeyu Zhu   +9 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

open access: yesBMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim   +9 more
wiley   +1 more source

A WGCNA‐Based Approach to Identify Hub Genes Associated With TNM Staging in Urothelial Bladder Carcinoma

open access: yesCancer Nexus, EarlyView.
ABSTRACT In this study, we identified gene modules and representative candidate biomarkers linked to clinical progression in patients with UBC. Weighted gene co‐expression network analysis (WGCNA) was used to identify gene modules associated with TNM staging in UBC patients.
Arshia Azmoudeh
wiley   +1 more source

Association of Urinary pH With Overall Survival in Patients With Stage IV Cancer: A Single‐Center Retrospective Cohort Study

open access: yesCancer Nexus, EarlyView.
ABSTRACT Objective This single‐center retrospective cohort study evaluated whether, among patients with stage IV cancer who participated in a pragmatic “alkalization therapy”—defined as a low potential renal acid load diet plus oral sodium bicarbonate and/or potassium/sodium citrate—urinary pH was associated with long‐term survival.
Shion Kachi   +5 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy